Shamburg News · 8-K filed Oct 1, 2026, 9:15 AM EDT
BioCardia Completes Revised FDA Pre-Submission for Helix Catheter
BCDA · BioCardia, Inc.
- Other event
- Materiality: medium
On October 1, 2026, BioCardia, Inc. reported it has completed its revised Pre-Submission to FDA CDRH under the Q-Submission program for approval of its Helix Catheter for therapeutic and diagnostic agent delivery to the heart. The company stated that FDA agreed to two pathways for Helix marketing clearance and raised no concerns regarding Helix safety data, device performance, or agent compatibility. The FDA targets an initial acceptance/refusal review within 15 calendar days and written feedback or a meeting within 70 calendar days.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001437749-26-031665.
Written from the filing by Shamburg Markets. Figures are as reported by the company.